Internal Server Error

Vitas Pharma - About the company

Vitas Pharma is a deadpooled company based in Hyderabad (India), founded in 2010 by Rajinder Kumar and Radha Rangarajan. It operates as an Indian, preclinical stage biopharma developing small molecule therapeutics for MDR bacterial infections (ESKAPE pathogens). Vitas Pharma has raised $484K in funding, with last known valuation of $*****. The company has 223 active competitors, including 78 funded and 40 that have exited. Its top competitors include companies like Spero Therapeutics, LimmaTech Biologics and Bioversys.

Company Details

Vitas Pharma is an Indian, preclinical stage biopharma developing small molecule therapeutics for MDR bacterial infections. The company focuses on infections that are usually acquired in hospitals. Its products are developed on its proprietary platform, called Tackling Antimicrobial Resistance through Novel Scaffolds (TARNS). It has a novel pipeline of molecules to treat infections caused by multidrug-resistant bacteria. Its lead product VT-02 for MRSA is in toxicology studies. The other candidates are VT-01 for gram-negative infections and VT-03 for Acinetobacter infections. The company is also developing companion diagnostics for the detection of Carbapenem resistance (Lab Testing stage) and MRSA detection (feasibility stage).
Email ID
*****@vitaspharma.com
Registered Address
PLOT NO.12, APARNA ORCHIDS MADHAPUR, HYDERABAD, Telangana, India, 500084
Key Metrics
Founded Year
2010
Location
Hyderabad, India
Stage
Deadpooled
Total Funding
$484K in 1 round
Latest Funding Round
Last Known Valuation
$***** as on Jan 17, 2015
Ranked
Annual Revenue
0 - ₹10 Cr as on Mar 31, 2020
Employee Count
6 as on Jul 01, 2024
Similar Companies
Sign up to download Vitas Pharma's company profile

Vitas Pharma's funding and investors

Vitas Pharma has raised a total funding of $484K over 1 round. Its latest funding round was a Seed round on Jan 17, 2015 for $*****. 43 investors participated in its latest round. Vitas Pharma has 12 institutional investors and 35 angel investors.

Here is the list of recent funding rounds of Vitas Pharma:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jan 17, 2015
1815918
Seed
2213599
5041788
3397859
1707479
lockAccess funding benchmarks and valuations. Sign up today!

Vitas Pharma's founders and board of directors

Founder? Claim Profile
The founders of Vitas Pharma are Rajinder Kumar and Radha Rangarajan.
Here are the details of Vitas Pharma's key team members:

Vitas Pharma's Board of Directors

Vitas Pharma's board has 2 active members. Rajinder Kumar and Radha Rangarajan are part of team.
Here is the list of Vitas Pharma's board of directors:
Name
Type
Representing
Status
Duration
Team
-
Current
16y 5m
jabvqyc
Team
-
Past
7y 1m

Vitas Pharma's employee count trend

Vitas Pharma has 6 employees as of Jul 24. Here is Vitas Pharma's employee count trend over the years:
Employee count trend for Vitas Pharma
lockUncover Vitas Pharma's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Vitas Pharma's Competitors and alternates

Top competitors of Vitas Pharma include Spero Therapeutics, LimmaTech Biologics and Bioversys. Here is the list of Top 10 competitors of Vitas Pharma, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Spero Therapeutics
Spero Therapeutics
2013, Cambridge (United States), Public
Developer of therapeutics for drug-resistant bacterial infections
$115M
67/100
2nd
Logo for LimmaTech Biologics
LimmaTech Biologics
2015, Schlieren (Switzerland), Acquired
Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques
$40M
65/100
3rd
Logo for Bioversys
Bioversys
2008, Basel (Switzerland), Public
Developer of therapeutics for Antimicrobial Resistance
$62.5M
63/100
4th
Logo for Locus Biosciences
Locus Biosciences
2015, Raleigh (United States), Series B
Developer of therapeutics for infectious disease and inflammatory indications
$67.3M
60/100
5th
Logo for Pattern Bioscience
Pattern Bioscience
2016, Austin (United States), Series C
Provider of multiple diagnostics platforms for infectious diseases
$105M
59/100
6th
Logo for smartbax
smartbax
2021, Munich (Germany), Seed
Developer of multi-targeted antibacterial compounds
$7.51M
59/100
7th
Logo for Everest Medicines
Everest Medicines
2017, New York City (United States), Public
Developer of drugs for the treatment of cancer
$313M
58/100
8th
Logo for Clarametyx
Clarametyx
2019, Columbus (United States), Series A
Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections
$33M
57/100
9th
Logo for Omnix Medical
Omnix Medical
2015, Jerusalem (Israel), Series C
Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections
$25M
57/100
10th
Logo for CARB-X
CARB-X
2016, Boston (United States), Funding Raised
Developer of antibiotics against-drug resistant bacteria
-
57/100
87th
Logo for Vitas Pharma
Vitas Pharma
2010, Hyderabad (India), Deadpooled
Indian, preclinical stage biopharma developing small molecule therapeutics for MDR bacterial infections (ESKAPE pathogens)
$484K
35/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Vitas Pharma's competitors? Click here to see the top ones

Financials of Vitas Pharma

VITAS PHARMA RESEARCH PRIVATE LIMITED, the legal entity associated with Vitas Pharma, generated less than ₹10 Cr in revenue for the financial year ending on Mar 31, 2020. The revenue of VITAS PHARMA RESEARCH PRIVATE LIMITED has a compounded annual growth rate (CAGR) of 32% in the last 1 year.

Financial Statement Summary

Metrics
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17
FY 2015-16
Income Statement
Revenue
4996
7773
9666
3337
7775
Total Sales
3791
3365
8568
5779
3326
Total Expenses
5999
8660
3320
4841
6964
Operating Expenses
9338
4657
4401
4775
4996
Employee Expenses
9728
5958
4148
6680
5798
Operating Income (EBIT)
2203
2126
5693
9979
8828
Interest Expenses
8668
3488
5115
7731
5271
Expenses from other activities
4821
1552
6063
2465
5762
EBITDA
3654
5638
1741
9997
1621
Taxes
5703
9913
4619
1499
5624
Net Profit
6429
1865
1542
8250
8147
Balance Sheet
Assets
5145
1765
4145
2014
3228
Accounts Receivables
8697
1982
5262
6852
3474
Inventory
4236
8113
4795
4126
1251
Liabilities
5553
6202
3696
8847
1239
Total Debt
7553
2667
5719
1441
2588
Accounts Payable
7763
9309
9524
5222
9875
Equities
2660
9046
6241
2726
1341

Detailed Financials (Income Statement, Balance Sheet, Cashflow Statement)

Gain deeper financial insights
of this entity
$10.99$2.53(excl. taxes)
Download Sample Report
What documents will you get?
  • Financial Summary & Charts
  • Detailed Income Statement, Balance Sheet, Cashflow Statement
  • Profitability Ratios, Liquidity Ratios, Growth Rates

Vitas Pharma's Latest cap tables and shareholding

Founders (largest shareholder) own 70.76%, Funds own 0.85%, Enterprises own 1.81% and Angels own 17.56%. The net worth of Vitas Pharma's founders is INR 10.5Cr as of Jan 17, 2015. The cap table displayed below is for VITAS PHARMA RESEARCH PRIVATE LIMITED which is the legal entity associated with Vitas Pharma.
Shareholders Name
Post Round Holding %
Net worth
Cumulative Investment
Realised Returns
Unrealised Returns
Return Multiple
Founder
70.76%
10.5Cr
1301742
2128527
6110732
4165145
3016688
9432946
4151144
1367087
7250932
7125197
2998750
6597537
3034516
4366056
7823265
8191837
Fund
0.85%
12.6L
0
0
0
0
Enterprise
1.81%
26.9L
7
4
8
3
Angel
17.56%
2.61Cr
3980654
9225152
3290098
2378301
8
8
1
4
6
6
0
0
0
0
0
0
ESOP Pool
9.03%
1.34Cr
7713026
1980826
9066597
1332005
Total
100.00%
14.8Cr
9720272
5206456
5106625
8153292
Notes: The column Net Worth represents the net worth of investments made by that entity, as per the latest cap table.
Disclaimer
Gain deeper insights into
shareholding pattern of this entity
$9.99$4.23(excl. taxes)
Download Sample Files
What documents will you get?
  • Latest Shareholding Summary - Ownership breakdown across founders, investors, and other stakeholders
  • Round-by-Round Cap Tables - Evolution of shareholding across funding rounds
  • Year-on-Year Cap Tables - Dilution trends over time

Vitas Pharma's Investments and acquisitions

Vitas Pharma has made no investments or acquisitions yet.

Reports related to Vitas Pharma

Here is the latest report on Vitas Pharma's sector:

FAQs about Vitas Pharma

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford